Cardiovascular benefits of digoxin and empagliflozin in patients with chronic heart failure: the DIG trial revisited

Cardiovascular benefits of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, in heart failure treatment continue to accumulate. Two large-scale trials have evaluated the effect of empagliflozin, a sodium –glucose co-transporter 2 (SGLT2) inhibitor, in patients with heart failure and a reduced ejection fraction (HFrEF) and patients with heart failure with a preserved ejection fraction (HFpEF).1, 2 Based on the EMPEROR-reduced trial, FDA recently approved empagliflozin to treat patients with HFrEF.

Source: The American Journal of Medicine - February 27, 2022 Category: General Medicine Authors: Haoyi Zheng Tags: Commentary Source Type: research